Skip to the stories
Daily Oracles

What changes next, and what it costs

Just published
Wellbeing

MHRA Women's Health Programme sets out plan to 2030 to fill gaps in evidence on medicines

The regulator wants sex-specific data built into how medicines and devices are tested and monitored, with pregnancy and breastfeeding a priority.

By Daily Oracles News Team2 min read

Macro photography of glasses on tray
Photograph: Nastya Dulhiier on Unsplash

Pregnant women were included in just 1.1% of the 4,616 clinical trial applications made in the UK between 2019 and 2023, and breastfeeding women in 0.6%. Those figures, from the Medicines and Healthcare products Regulatory Agency's own analysis, are the starting point for a Women's Health Programme the regulator launched on Monday.

The programme runs to 2030 and is meant to change how evidence about women is collected at every stage of a product's life, from early trials through licensing to monitoring once a medicine or device is in use. The MHRA also notes that only 33% of trials it approved between 2019 and 2023 included women of childbearing potential, and that women are reported to have adverse reactions more often, without it yet being clear whether that reflects a genuine difference in susceptibility.

Four themes

Data. Companies will be asked to submit results broken down by sex in a consistent way, and the MHRA plans to use real-world data, including patient-reported outcome measures, and work with NHS organisations to spot where medicines or devices perform differently in women. Where evidence allows, more of this will appear in product information.

Innovation. The regulator wants clearer rules for FemTech, the technology aimed at women's health, and will publish topics of regulatory interest to encourage developers to come forward early.

Pregnancy and breastfeeding. It will pilot new ways of gathering safety evidence for priority products and issue guidance on including pregnant and breastfeeding women in research. The MHRA wants patient leaflets to reflect the evidence that does exist, so that a lack of information does not put women off treatments they could use.

Reach and impact. The MHRA will publish guidance on communicating sex-based differences in outcomes to patients and healthcare professionals, and set up frameworks for working with other parts of the health system on sex-based health inequalities.

The themes were co-designed with patients, including through the MHRA's Patient and Public Community and a Patients Association focus group. The agency already plans to widen that community's membership under its patient involvement plan to 2030.

Money and timing

The programme document cites estimates that closing the gap in health outcomes between women and men could add at least £36bn a year to the UK economy by 2040. The UK FemTech sector has annual turnover of nearly £300m and has attracted £544m of investment, according to a 2026 industry report quoted by the MHRA.

The programme was announced at the first DIA-MHRA Global Summit in London, which runs on 16 and 17 November as part of London Life Sciences Week. It forms the MHRA's regulatory part of the renewed Women's Health Strategy for England, with related work in Scotland, Wales and Northern Ireland, and is the first piece of a wider effort on health inequalities under the agency's 2030 strategy.

The MHRA will explain the plans in a webinar on Wednesday 9 December, from 11am to 12pm, with registration through Eventbrite.

Read next

Know about a change before it lands?

Businesses, councils, charities and readers tell us about new prices, plans and launches. If it will change what people pay or how they work, we want to hear it.

Submit your story